Onyx Raises $185 Million On Nexavar Data In Liver Cancer

Morrison, Trista
June 2007
BioWorld Today;6/22/2007, Vol. 18 Issue 121, p1
The article reports that Onyx Pharmaceuticals Inc. is raising $185 million in response to the positive prospects of its kidney cancer drug Nexavar. Onyx will be offering 6.6 million shares at $28 per share in a transaction managed and underwritten by Morgan Stanley & Co. Inc. and Merrill Lynch & Co. Net revenue from Nexavar was $60.9 million in the first quarter.


Related Articles

  • EARNINGS ROUNDUP.  // BioWorld Today;5/8/2009, Vol. 20 Issue 88, p7 

    The article reports on the increase in the global net sales of cancer drug Nexavar in the first quarter of 2009, according to Onyx Pharmaceuticals Inc. Sales totaled $178.1 million, up 17 percent in the same period last year. The company had $467.1 million in cash, equivalents and marketable...

  • Onyx Will Develop Cancer Drug in $320M BTG Deal. Hollingsworth, Catherine // BioWorld International;11/12/2008, Vol. 13 Issue 46, p1 

    The article reports on the licensing deal reached by Onyx Pharmaceuticals Inc. for the anticancer compound of BTG plc in November 2008. Onyx reportedly plans to expand Nexavar, a treatment for kidney and liver cancer. Information on the pharmacokinetics of the drug is offered. The financial...

  • EARNINGS ROUNDUP.  // BioWorld Today;5/6/2010, Vol. 21 Issue 87, p10 

    This article reports on the global net sales of cancer drug Nexavar from Onyx Pharmaceuticals Inc. in the first quarter of 2010.

  • Onyx Soars as Nexavar Hits Goal in Breast Cancer Trial. Boggs, Jennifer // BioWorld Today;7/23/2009, Vol. 20 Issue 140, p1 

    This article reports on an increase in shares of Onyx Pharmaceuticals Inc. following the release of top-line results of a Phase II trial of its multikinase inhibitor Nexavar in 2009. The company's shares grew 21 percent. According to Onyx, the drug met the primary endpoint in the clinical trial...

  • Onyx, Bayer get jump on cancer drug. Mirasol, Feliza // Chemical Market Reporter;9/26/2005, Vol. 268 Issue 10, p24 

    Reports on the efforts made by Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. to bring their new anticancer drug sorafenib to the U.S. market. Drug approval sought the pharmaceutical firms from the Food and Drug Administration; Optimism of analysts on the long-term viability of the...

  • Proteolix Will Be Acquired by Onyx.  // Chain Drug Review;10/26/2009, Vol. 31 Issue 18, p74 

    The article reports on the plan of Onyx Pharmaceuticals Inc. to acquire Proteolix Inc. in the U.S. According to Onyx, it will purchase the cancer drug developer in a deal that could be worth as much as 851 million dollars. Onyx will pay 276 million dollars up front, 40 million dollars for...

  • Amgen-Onyx Pharmaceuticals Back For Round Two? Big Biotechs are Mum. Powers, Marie // BioWorld Today;8/8/2013, Vol. 24 Issue 151, p1 

    The article reports on speculation of another bid of Amgen Inc. for Onyx Pharmaceuticals Inc. which is higher from its unsolicited bid in late June 2013. In the first bid, Amgen has offered 120 U.S. dollars per share which represented a 38 percent premium over the closing price for Onyx shares...

  • Big M&A Deals Long Overdue?  // BioWorld Today;8/8/2013, Vol. 24 Issue 151, p3 

    The article speculates on the possible merger and acquisition (M&A) deal between biotechnology and pharmaceutical firms Amgen and Onyx. Analysts said that the industry is expected to have more M&A deals in the fourth quarter of 2013. It notes that Amgen is in good financial situation having...

  • Earnings Roundup.  // BioWorld Today;11/5/2012, Vol. 23 Issue 215, p5 

    This article reports on the net sales posted by Onyx Pharmaceuticals Inc. for its cancer drug Kyprolis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics